Notably, inhibitors of the HGF/c-Met and TGF-β signaling pathways, such as Cabozantinib27 and Fresolimumab28, have been involved in clinical trials for breast cancer and showed benefits in metastasis patients, suggesting their potential as novel therapies for breast cancer. This evidence concerns the gene TGFB1 and breast cancer.